שווי פעילות לרווח לפני ריבית, מסים ופחת BiomX (PHGE)

This chart of EV/EBITDA valuation for BiomX Inc. (PHGE) is recorded at 0.00. Demand for the treatment of resistant bacteria makes the business independent of economic cycles, relying instead on test results and patents. Drug development is conducted through partnerships with industry behemoths, while the loyalty of the expert microbiologist staff is secured via a flexible stock option system.

This metric compares the total enterprise value, including net debt, to its operating profit before depreciation and amortization, determining the investment payback period without considering tax effects. Amid the R&D portfolio restructuring of BiomX Inc. (PHGE), the EV/EBITDA ratio, accounting for operating profit and amortization, allows for an assessment of asset management efficiency and the cost of corporate control against the backdrop of accelerated clinical trials.